Skip to content

Modified LERV for secondary choledocholithiasis: a single-center, non-randomized, controlled clinical study

Modified LERV for secondary choledocholithiasis: a single-center, non-randomized, controlled clinical study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063241
Enrollment
Unknown
Registered
2022-09-02
Start date
2022-09-02
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

choledocholithiasis

Interventions

LERV group:LERV was used to treat choledocholithiasis
ERCP+LC group:Choledocholithiasis was treated by ERCP+LC

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The subjects voluntarily joined the study and signed the informed consent; 2. Aged 18-85 years; 3. Clinically diagnosed as cholecystolithiasis secondary to choledocholithiasis and the diameter of the middle choledocholithiasis (MCBD) <= 10mm; MCBD diameter is measured by MRCP. If MRCP cannot be performed, CT images shall be referred to and b-ultrasound measurements shall be taken as the standard; 4. Good cardiopulmonary function, anesthesia evaluation tolerance of laparoscopic and endoscopic surgery under general anesthesia.

Exclusion criteria

Exclusion criteria: 1. Patients with intrahepatic bile duct stones with surgical indications and requiring simultaneous operation; 2. patients with choledocholithiasis >2 cm or a large number of choledocholithiasis; 3. patients with malignant hepatobiliary and pancreatic tumors or biliary malformation; 4. Patients with severe pancreatitis and septic shock before surgery; 5. Patients with a history of gastroduodenoscopic surgery and gastroduodenal continuity interruption; 6. Severe partial stenosis of the upper digestive tract (from the oral cavity to the second duodenum), which is expected to be impossible to pass through the duodenoscope.

Design outcomes

Primary

MeasureTime frame
Success rate of stone extraction;

Secondary

MeasureTime frame
The incidence of post-ERCP pancreatitis;length of stay;hospitalization costs;

Countries

China

Contacts

Public ContactZhan Yongqiang

Shenzhen Second People's Hospital

yqzhan@sina.com+86 13714096676

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026